Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Jeffrey Flier, former Dean at Harvard Medical School, writes in STAT on How Pfizer ended up passing on my GLP-1 work back in the early 90s. Flier kicks off with Despite extremely promising results, Pfizer, the major funder of the work in alliance with California Biotechnology, abandoned the effort around 1991 after mistakenly concluding that the GLP-1 therapeutic approach was not worth continuing. He states that he is not trying to take credit for the GLP-1 market, rather that the story offers valuable lessons on drug development for pharmaceutical companies, researchers, and the general public alike. The article describes the early stages of drug development and testing from 1987, with Pfizer against an injectable GLP-1 version, and a focus on a way to deliver GLP-1 via transnasal, transcutaneous, or oral administration
This three-pronged approach is what makes its weight loss numbers so much higher than previous generation compounds
Cole JB, Florez JC
Clean & Thoughtful Ingredients Made with carefully sourced ingredients and manufactured following quality standards for dietary supplements
Focus: Assessing personal peptide tolerance and GI adaptation
